In a recent Phase 2 study presented in June 2025, combining it with semaglutide (the active ingredient in Wegovy) led to remarkable outcomes for participants with obesity: An average weight loss of 22% over 72 weeks (compared to 16% with semaglutide alone) About 93% of that loss coming from fat mass, with minimal impact on lean muscle A 58% drop in visceral fat (versus 36% with semaglutide alone) All achieved without requiring dietary or exercise modifications This stands out because typical weight-loss drugs, like GLP-1 agonists, often result in losing both fat and musclea downside, since muscle boosts metabolism and supports overall health as we age
Fast, tracked delivery to the UK and Ireland
I was trying to eat more healthily, but I still put the weight back on. The presenter and producer is now back on the GLP-1, which she compared to blood pressure medication
For women with lipedema, weight reduction can help decrease the pressure on the lymphatic system, potentially reducing the severity of symptoms such as pain and mobility issues
Please refer to the on-site announcement at the store
The safety and effectiveness of Wegovy tablets have not been established in pediatric patients